Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.

Gregory E Sanda,Julie M Shabto,Subir Goyal,Yuan Liu,Dylan J Martini,Bassel Nazha,Jacqueline T Brown,Lauren B Yantorni,Greta Anne Russler,Sarah Caulfield,Shreyas S Joshi,Vikram M Narayan,Haydn Kissick,Kenneth Ogan,Viraj A Master,Bradley C Carthon,Omer Kucuk,Mehmet Asim Bilen

The oncologist（2023）

引用 0|浏览30

暂无评分

摘要

Of patients with advanced UC that had undergone ICI therapy, those who had irAEs, especially dermatologic irAEs, had significantly greater OS, PFS, and CB. These results may suggest that irAE's may serve as an important marker of durable response to ICI therapy in urothelial cancer. The findings of this study need to be validated with larger cohort studies in the future.

查看译文

关键词

immune-related adverse events, urothelial cancer, bladder cancer, checkpoint inhibitor, outcomes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要